3D Global Biotech Inc.(TW:6808)
NT$26.10+0.10 (+0.38%)
TW:6808
3D Global Biotech Inc. financials statements
NT$26.10
At close:+0.10 (+0.38%)
3D Global Biotech Inc. (6808) Ratios
3D Global Biotech Inc. Ratios
TW:6808's free cash flow for Q2 2026 was NT$21.06M. For the 2026 fiscal year, TW:6808's free cash flow was decreased by NT$-12.29M and operating cash flow was NT$33.35M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 14.08 | 15.93 | 6.63 | 10.71 | 16.04 |
| Quick Ratio | 13.53 | 15.80 | 6.49 | 10.54 | 15.99 |
| Cash Ratio | 0.43 | 1.07 | 0.82 | 0.77 | 1.36 |
| Solvency Ratio | 0.89 | 0.85 | -1.14 | -1.34 | -1.00 |
| Operating Cash Flow Ratio | 2.72 | 0.37 | -1.19 | -1.71 | -2.41 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 468.39M | NT$ 702.93M | NT$ 144.99M | NT$ 185.35M | NT$ 205.04M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.08 | 0.03 | 0.05 | 0.05 |
| Debt-to-Equity Ratio | 0.05 | 0.09 | 0.04 | 0.05 | 0.05 |
| Debt-to-Capital Ratio | 0.05 | 0.09 | 0.03 | 0.05 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.11 | 1.15 | 1.10 | 1.09 | 1.09 |
| Debt Service Coverage Ratio | 59.47 | 979.76 | -198.19 | -160.65 | -132.40 |
| Interest Coverage Ratio | 29.59 | 764.67 | -357.12 | -259.95 | -238.35 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.64 | 1.23 | 0.19 | 0.31 | 0.40 |
| Net Debt to EBITDA | 0.45 | 0.24 | 0.32 | -0.02 | -0.03 |
| Profitability Margins | |||||
| Gross Profit Margin | 61.67% | 65.68% | 25.56% | 19.91% | 16.28% |
| EBIT Margin | 20.05% | 36.20% | -284.68% | -607.48% | -548.14% |
| EBITDA Margin | 33.43% | 44.42% | -173.73% | -417.91% | -323.42% |
| Operating Profit Margin | 20.05% | 33.39% | -304.62% | -485.87% | -561.71% |
| Pretax Profit Margin | 25.30% | 36.16% | -285.54% | -609.35% | -550.49% |
| Net Profit Margin | 32.18% | 34.51% | -280.87% | -491.72% | -539.10% |
| Continuous Operations Profit Margin | 32.18% | 34.51% | -280.87% | -491.72% | -539.10% |
| Net Income Per EBT | 127.19% | 95.45% | 98.36% | 80.70% | 97.93% |
| EBT Per EBIT | 126.18% | 108.31% | 93.73% | 125.42% | 98.00% |
| Return on Assets (ROA) | 6.10% | 8.84% | -17.88% | -18.07% | -14.06% |
| Return on Equity (ROE) | 6.76% | 10.14% | -19.75% | -19.70% | -15.32% |
| Return on Capital Employed (ROCE) | 3.95% | 9.00% | -21.12% | -18.88% | -15.19% |
| Return on Invested Capital (ROIC) | 3.92% | 8.50% | -20.34% | -14.96% | -14.68% |
| Return on Tangible Assets | 6.54% | 9.65% | -26.12% | -26.39% | -21.93% |
| Earnings Yield | 1.77% | 2.00% | -5.37% | -4.60% | -2.82% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.86 | 2.17 | 10.66 | 8.91 | 6.75 |
| Payables Turnover | 28.64 | 5.67 | 4.61 | 4.91 | 13.94 |
| Inventory Turnover | 3.54 | 12.94 | 4.27 | 3.24 | 10.50 |
| Fixed Asset Turnover | 3.46 | 2.86 | 1.57 | 0.65 | 0.39 |
| Asset Turnover | 0.19 | 0.26 | 0.06 | 0.04 | 0.03 |
| Working Capital Turnover Ratio | 0.31 | 0.57 | 0.12 | 0.06 | 0.04 |
| Cash Conversion Cycle | 218.07 | 131.95 | 40.52 | 79.24 | 62.66 |
| Days of Sales Outstanding | 127.71 | 168.13 | 34.25 | 40.96 | 54.08 |
| Days of Inventory Outstanding | 103.11 | 28.20 | 85.43 | 112.57 | 34.76 |
| Days of Payables Outstanding | 12.74 | 64.38 | 79.16 | 74.29 | 26.18 |
| Operating Cycle | 230.82 | 196.33 | 119.68 | 153.53 | 88.84 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.43 | 0.29 | -0.56 | -0.63 | -0.67 |
| Free Cash Flow Per Share | 1.35 | 0.21 | -0.58 | -0.64 | -0.72 |
| Dividend Paid and CapEx Coverage Ratio | 2.33 | 4.00 | -40.63 | -40.29 | -12.47 |
| Capital Expenditure Coverage Ratio | 17.59 | 4.00 | -40.63 | -40.29 | -12.47 |
| Operating Cash Flow Coverage Ratio | 2.28 | 0.23 | -3.05 | -2.06 | -1.69 |
| Operating Cash Flow to Sales Ratio | 0.54 | 0.07 | -1.53 | -2.53 | -3.25 |
| Free Cash Flow Yield | 2.79% | 0.32% | -3.00% | -2.42% | -1.84% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 56.16 | 50.23 | -18.63 | -21.79 | -35.28 |
| Price-to-Sales (P/S) Ratio | 18.14 | 17.28 | 52.33 | 106.92 | 190.83 |
| Price-to-Book (P/B) Ratio | 3.81 | 5.08 | 3.68 | 4.28 | 5.42 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 35.86 | 311.53 | -33.33 | -41.27 | -54.37 |
| Price-to-Operating Cash Flow Ratio | 33.82 | 233.66 | -34.15 | -42.30 | -58.73 |
| Price-to-Earnings Growth (PEG) Ratio | -1.59 | -0.22 | 1.20 | -2.20 | -1.43 |
| Enterprise Value Multiple | 54.73 | 39.15 | -29.80 | -25.61 | -59.03 |
| Enterprise Value | 3.78B | 4.62B | 1.07B | 1.46B | 2.11B |
| EV to EBITDA | 54.73 | 39.15 | -29.80 | -25.61 | -59.03 |
| EV to Sales | 18.29 | 17.39 | 51.77 | 107.01 | 190.92 |
| EV to Free Cash Flow | 36.16 | 313.47 | -32.98 | -41.31 | -54.39 |
| EV to Operating Cash Flow | 34.10 | 235.12 | -33.79 | -42.33 | -58.75 |
| Tangible Book Value Per Share | 11.74 | 11.88 | 3.40 | 4.07 | 4.40 |
| Shareholders’ Equity Per Share | 12.68 | 13.16 | 5.22 | 6.21 | 7.22 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.27 | 0.05 | 0.02 | 0.19 | 0.02 |
| Revenue Per Share | 2.66 | 3.86 | 0.37 | 0.25 | 0.21 |
| Net Income Per Share | 0.86 | 1.33 | -1.03 | -1.22 | -1.11 |
| Tax Burden | 1.27 | 0.95 | 0.98 | 0.81 | 0.98 |
| Interest Burden | 1.26 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.18 | 0.16 | 1.87 | 2.89 | 3.39 |
| SG&A to Revenue | 0.23 | 0.16 | 1.43 | 2.16 | 2.38 |
| Stock-Based Compensation to Revenue | 0.02 | 0.02 | 0.01 | 0.02 | 0.05 |
| Income Quality | 2.12 | 0.20 | 0.55 | 0.51 | 0.59 |
Currency in TWD
